Page last updated: 2024-09-04

vatalanib and Melanoma

vatalanib has been researched along with Melanoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J1
Basu, B; Biswas, S; Cook, N; Corrie, PG; Kareclas, P; Lomas, D; Mander, AP; Mann, C; Middleton, M; Morgan, B; Nicholson, S; Palmer, C; Sirohi, B; Thomas, A1
Kiziltepe, T; Sasisekharan, R; Sengupta, S1
Allegrini, PR; Baumann, D; Becquet, M; Brecht, K; Brueggen, J; Ferretti, S; McSheehy, PM; Rausch, M; Rudin, M; Schaeffer, F; Schnell, C; Wood, J1

Trials

1 trial(s) available for vatalanib and Melanoma

ArticleYear
A phase 2 study of vatalanib in metastatic melanoma patients.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Phthalazines; Pyridines; Skin Neoplasms; Treatment Outcome; Young Adult

2010

Other Studies

3 other study(ies) available for vatalanib and Melanoma

ArticleYear
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
    Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26

    Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor

2002
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:13

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A

2004
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    NMR in biomedicine, 2005, Volume: 18, Issue:5

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A

2005